Supernus Pharmaceuticals, Inc. (SUPN) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
51.45
↑+118% vs avg
5yr avg: 23.56
30Y Low7.7·High51.1
P/FCF
↑
61.38
↑+158% vs avg
5yr avg: 23.78
30Y Low9.1·High61.0
P/B Ratio
↑
2.61
↑+21% vs avg
5yr avg: 2.15
30Y Low1.7·High7.9
ROE
↓
-3.7%
↑-202% vs avg
5yr avg: 3.6%
30Y Low-203%·High59%
Debt/EBITDA
↓
0.77
↓-55% vs avg
5yr avg: 1.70
30Y Low0.1·High14.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SUPN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Supernus Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 61.4x P/FCF, 158% above the 5-year average of 23.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.8B | $2.8B | $2.0B | $1.6B | $2.2B | $1.6B | $1.4B | $1.3B | $1.8B | $2.1B | $1.3B |
| Enterprise Value | $2.7B | $2.7B | $2.0B | $1.6B | $2.6B | $1.8B | $1.5B | $1.5B | $1.9B | $2.1B | $1.2B |
| P/E Ratio → | -72.10 | — | 27.39 | 1221.10 | 34.30 | 29.76 | 10.66 | 11.30 | 16.20 | 36.90 | 14.35 |
| P/S Ratio | 3.93 | 3.90 | 3.06 | 2.64 | 3.30 | 2.73 | 2.60 | 3.25 | 4.40 | 7.03 | 6.07 |
| P/B Ratio | 2.61 | 2.64 | 1.95 | 1.74 | 2.48 | 1.94 | 1.81 | 2.14 | 3.97 | 7.94 | 6.81 |
| P/FCF | 61.38 | 61.00 | 11.82 | 14.53 | 18.90 | 12.67 | 10.01 | 9.09 | 14.02 | 18.86 | 20.02 |
| P/OCF | 59.65 | 59.28 | 11.77 | 14.46 | 18.83 | 12.47 | 9.76 | 8.92 | 13.93 | 18.53 | 19.54 |
P/E links to full P/E history page with 30-year chart
SUPN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Supernus Pharmaceuticals, Inc.'s enterprise value stands at 51.5x EBITDA, 118% above its 5-year average of 23.6x. The Healthcare sector median is 14.0x, placing the stock at a 267% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.78 | 3.00 | 2.59 | 3.82 | 3.12 | 2.84 | 3.75 | 4.73 | 6.78 | 5.67 |
| EV / EBITDA | 51.45 | 51.12 | 12.27 | 19.76 | 19.38 | 15.25 | 7.70 | 9.28 | 12.77 | 19.04 | 21.54 |
| EV / EBIT | — | — | 20.32 | 303.40 | 37.63 | 18.72 | 7.67 | 8.66 | 13.39 | 20.60 | 22.50 |
| EV / FCF | — | 59.10 | 11.61 | 14.23 | 21.92 | 14.46 | 10.94 | 10.50 | 15.10 | 18.21 | 18.70 |
SUPN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Supernus Pharmaceuticals, Inc. earns an operating margin of -5.1%. Operating margins have compressed from -0.9% to -5.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -3.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.6% | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% | 95.8% | 96.2% | 95.0% | 94.4% |
| Operating Margin | -5.1% | -5.1% | 12.3% | -0.9% | 6.9% | 14.8% | 33.4% | 37.8% | 35.3% | 32.9% | 25.2% |
| Net Profit Margin | -5.4% | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.7% | -3.7% | 7.5% | 0.1% | 7.1% | 6.8% | 18.9% | 21.6% | 30.8% | 24.9% | 58.7% |
| ROA | -2.7% | -2.7% | 5.6% | 0.1% | 3.6% | 3.3% | 9.5% | 10.6% | 15.8% | 15.6% | 36.6% |
| ROIC | -2.8% | -2.8% | 6.5% | -0.4% | 3.0% | 6.8% | 15.7% | 16.1% | 27.6% | 49.9% | 47.9% |
| ROCE | -3.4% | -3.4% | 7.9% | -0.5% | 3.9% | 6.5% | 15.4% | 16.4% | 25.8% | 37.5% | 30.0% |
SUPN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Supernus Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.8x, which is very conservative (75% below the sector average of 3.1x). The company holds a net cash position — cash of $128M exceeds total debt of $41M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.03 | 0.05 | 0.50 | 0.52 | 0.56 | 0.64 | 0.73 | 0.10 | 0.02 |
| Debt / EBITDA | 0.77 | 0.77 | 0.21 | 0.52 | 3.38 | 3.60 | 2.16 | 2.38 | 2.17 | 0.25 | 0.07 |
| Net Debt / Equity | — | -0.08 | -0.03 | -0.04 | 0.40 | 0.27 | 0.17 | 0.33 | 0.30 | -0.28 | -0.45 |
| Net Debt / EBITDA | -1.65 | -1.65 | -0.22 | -0.42 | 2.67 | 1.88 | 0.66 | 1.24 | 0.91 | -0.69 | -1.52 |
| Debt / FCF | — | -1.90 | -0.20 | -0.30 | 3.02 | 1.79 | 0.93 | 1.40 | 1.07 | -0.66 | -1.32 |
| Interest Coverage | — | — | — | 2.15 | 9.59 | 4.12 | 8.10 | 7.50 | 7.98 | 63.48 | 10.65 |
Net cash position: cash ($128M) exceeds total debt ($41M)
SUPN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.90x means Supernus Pharmaceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.70x to 1.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.90 | 1.90 | 2.35 | 1.70 | 1.07 | 1.91 | 2.57 | 2.94 | 3.06 | 1.86 | 1.88 |
| Quick Ratio | 1.66 | 1.66 | 2.16 | 1.43 | 0.93 | 1.63 | 2.37 | 2.78 | 2.90 | 1.72 | 1.67 |
| Cash Ratio | 0.91 | 0.91 | 1.55 | 0.88 | 0.67 | 1.08 | 1.72 | 2.16 | 2.21 | 1.14 | 1.12 |
| Asset Turnover | — | 0.49 | 0.48 | 0.48 | 0.39 | 0.34 | 0.35 | 0.34 | 0.42 | 0.71 | 0.69 |
| Inventory Turnover | 0.91 | 0.91 | 1.43 | 1.08 | 0.95 | 0.87 | 1.09 | 0.63 | 0.60 | 0.93 | 0.71 |
| Days Sales Outstanding | — | 95.34 | 78.36 | 86.61 | 90.53 | 93.76 | 98.81 | 81.16 | 91.87 | 79.21 | 70.50 |
SUPN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Supernus Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 3.7% | 0.1% | 2.9% | 3.4% | 9.4% | 8.9% | 6.2% | 2.7% | 7.0% |
| FCF Yield | 1.6% | 1.6% | 8.5% | 6.9% | 5.3% | 7.9% | 10.0% | 11.0% | 7.1% | 5.3% | 5.0% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $56M | $56M | $56M | $62M | $54M | $54M | $54M | $54M | $53M | $52M |
Peer Comparison
Compare SUPN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SUPNYou | $3B | -72.1 | 51.5 | 61.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.8 |
 PCRX | $975M | 154.9 | 10.2 | 7.1 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 ACAD | $4B | 16.4 | 14.2 | 24.0 | 91.5% | 24.1% | 38.9% | 45.2% | 0.2 |
 INVA | $2B | 6.9 | 5.6 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
 PRGO | $2B | -1.1 | — | 11.0 | 35.1% | -26.4% | -39.3% | -17.1% | — |
 LNTH | $6B | 25.2 | 13.7 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 HRMY | $2B | 11.9 | 4.9 | 5.4 | 77.2% | 24.0% | 20.8% | 59.5% | 0.1 |
 AXSM | $11B | -60.6 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 NKTR | $2B | -8.6 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 LGND | $5B | -1055.9 | 356.3 | 59.0 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 CORT | $6B | 62.6 | 115.6 | 38.9 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See SUPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SUPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SUPN vs PCRX
Side-by-side business, growth, and profitability comparison vs Pacira BioSciences, Inc..
Start ComparisonSUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
What is Supernus Pharmaceuticals, Inc.'s P/E ratio?
Supernus Pharmaceuticals, Inc.'s current P/E ratio is -72.1x. The historical average is 25.5x.
What is Supernus Pharmaceuticals, Inc.'s EV/EBITDA?
Supernus Pharmaceuticals, Inc.'s current EV/EBITDA is 51.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.7x.
What is Supernus Pharmaceuticals, Inc.'s ROE?
Supernus Pharmaceuticals, Inc.'s return on equity (ROE) is -3.7%. The historical average is -8.2%.
Is SUPN stock overvalued?
Based on historical data, Supernus Pharmaceuticals, Inc. is trading at a P/E of -72.1x. Compare with industry peers and growth rates for a complete picture.
What are Supernus Pharmaceuticals, Inc.'s profit margins?
Supernus Pharmaceuticals, Inc. has 89.6% gross margin and -5.1% operating margin.
How much debt does Supernus Pharmaceuticals, Inc. have?
Supernus Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.8x, indicating low leverage. A ratio below 2x is generally considered financially healthy.